Financial overview

Circio financial report data and keyfigures. History for income statement, balance sheet and cash flow.

Pre
Pre
Pre

Description

Targovax ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing highly targeted immunotherapy treatments for cancer patients.

Biotechnology